SPIMACO’s H1 profit drops 41% on zakat expenses

SPIMACO’s H1 profit drops 41% on zakat expenses

01/08/2018 Argaam Exclusive

View other reports

Saudi Pharmaceutical Industries Medical Appliances Corp. (SPIMACO) reported a net profit of SAR 91.3 million for H1 2018, a fall of 40.5 percent year-on-year (YoY), on incurring zakat expenses at SAR 21 million, compared to zero charges in H1 2017.

 

The company had also recorded one-off gains of SAR 46 million from selling securities investments in the first half of 2017.



Financials (M)

Item 6m 2017 6m 2018 Change‬
Revenues 697.74 677.58 (2.9 %)
Gross Income 368.71 342.84 (7.0 %)
Operating Income 99.43 65.80 (33.8 %)
Net Income 147.78 69.69 (52.8 %)
Average Shares 120.00 120.00 -
EPS (Riyals) 1.23 0.58 (52.8 %)

The Q2 net profit decreased by 33.6 percent YoY to SAR 35.5 million, hurt by an increase in operating, selling, general and administrative expenses, as well as doubtful loan provisions.

 

When compared to Q1 2018, the company’s net earnings also dropped 36.4 percent, due to a decline in revenue and seasonal factors.



Current Quarter Comparison (M)

Compared With The
Item Q2 2017 Q2 2018 Change‬
Revenues 304.63 295.62 (3.0 %)
Gross Income 156.13 155.28 (0.5 %)
Operating Income 49.40 10.00 (79.8 %)
Net Income 46.56 22.67 (51.3 %)
Average Shares 120.00 120.00 -
EPS (Riyals) 0.39 0.19 (51.3 %)


Financial results (Million)

Period Revenues Change Gross Income Change Net Income Change EPS(Riyal)
Q1 2009 257.88 16.9 % 108.57 9.0 % 42.69 4.3 % 0.42
Q2 2009 229.00 8.2 % 81.53 9.0 % 37.81 10.4 % 0.37
Q3 2009 171.15 17.7 % 72.49 (2.5 %) 15.84 1.4 % 0.16
Q4 2009 292.71 (0.5 %) 157.00 37.4 % 58.48 56.0 % 0.58
Q1 2010 274.33 6.4 % 118.90 9.5 % 45.32 6.2 % 0.38
Q2 2010 252.34 10.2 % 100.50 23.3 % 43.09 14.0 % 0.36
Q3 2010 191.40 11.8 % 85.88 18.5 % 18.07 14.1 % 0.15
Q4 2010 319.57 9.2 % 181.12 15.4 % 70.04 19.8 % 0.58
Q1 2011 252.08 (8.1 %) 123.51 3.9 % 45.71 0.9 % 0.38
Q2 2011 292.08 15.7 % 123.61 23.0 % 60.75 41.0 % 0.51
Q3 2011 209.24 9.3 % 106.76 24.3 % 29.75 64.6 % 0.25
Q4 2011 375.82 17.6 % 206.69 14.1 % 74.06 5.7 % 0.62
Q1 2012 303.14 20.3 % 153.21 24.0 % 56.45 23.5 % 0.47
Q2 2012 286.64 (1.9 %) 140.91 14.0 % 90.14 48.4 % 0.75
Q3 2012 227.40 8.7 % 113.28 6.1 % 32.33 8.7 % 0.27
Q4 2012 365.97 (2.6 %) 211.16 2.2 % 53.73 (27.5 %) 0.45
Q1 2013 361.37 19.2 % 184.62 20.5 % 63.15 11.9 % 0.53
Q2 2013 344.22 20.1 % 179.12 27.1 % 113.71 26.1 % 0.95
Q3 2013 222.91 (2.0 %) 118.64 4.7 % 34.19 5.8 % 0.28
Q4 2013 382.01 4.4 % 226.14 7.1 % 57.01 6.1 % 0.48
Q1 2014 405.21 12.1 % 206.72 12.0 % 91.17 44.4 % 0.76
Q2 2014 371.14 7.8 % 193.14 7.8 % 97.72 (14.1 %) 0.81
Q3 2014 266.02 19.3 % 134.45 13.3 % 36.69 7.3 % 0.31
Q4 2014 431.06 12.8 % 261.80 15.8 % 91.29 60.1 % 0.76
Q1 2015 432.20 6.7 % 225.86 9.3 % 99.39 9.0 % 0.83
Q2 2015 435.80 17.4 % 210.95 9.2 % 237.63 143.2 % 1.98
Q3 2015 308.27 15.9 % 131.32 (2.3 %) 29.16 (20.5 %) 0.24
Q4 2015 520.38 20.7 % 266.38 1.7 % (9.12) (110.0 %) (0.08)
Q1 2016 322.20 (25.4 %) 194.26 (14.0 %) 88.91 (10.5 %) 0.74
Q2 2016 339.54 (22.1 %) 183.58 (13.0 %) 39.61 (83.3 %) 0.33
Q3 2016 257.21 (16.6 %) 140.54 7.0 % 4.76 (83.7 %) 0.04
Q4 2016 339.59 (34.7 %) 194.16 (27.1 %) 143.48 1673.8 % 1.20
Q1 2017 393.10 22.0 % 212.58 9.4 % 101.22 13.8 % 0.84
Q2 2017 304.63 (10.3 %) 156.13 (15.0 %) 46.56 17.5 % 0.39
Q3 2017 277.62 7.9 % 128.68 (8.4 %) (17.03) (457.9 %) (0.14)
Q4 2017 410.69 20.9 % 207.07 6.7 % 66.61 (53.6 %) 0.56
Q1 2018 390.79 (0.6 %) 197.32 (7.2 %) 55.23 (45.4 %) 0.46
Q2 2018 295.62 (3.0 %) 155.28 (0.5 %) 22.67 (51.3 %) 0.19

Profitability

Period Gross Margin OIBDA Margin Net Margin Before Unusual Items
Q1 2009 40.91 % 16.13 % 14.83 %
Q2 2009 40.87 % 16.44 % 14.89 %
Q3 2009 39.57 % 15.73 % 14.07 %
Q4 2009 44.13 % 18.49 % 16.63 %
Q1 2010 44.45 % 18.88 % 16.94 %
Q2 2010 45.32 % 18.93 % 17.07 %
Q3 2010 45.73 % 18.73 % 16.95 %
Q4 2010 46.88 % 18.85 % 17.32 %
Q1 2011 48.36 % 18.99 % 17.42 %
Q2 2011 48.73 % 19.12 % 18.44 %
Q3 2011 49.86 % 19.99 % 19.22 %
Q4 2011 49.64 % 19.57 % 18.62 %
Q1 2012 50.01 % 19.86 % 18.73 %
Q2 2012 51.72 % 20.36 % 21.31 %
Q3 2012 51.47 % 20.54 % 21.21 %
Q4 2012 52.28 % 19.56 % 19.66 %
Q1 2013 52.36 % 19.26 % 19.28 %
Q2 2013 52.98 % 18.87 % 20.24 %
Q3 2013 53.58 % 18.66 % 20.45 %
Q4 2013 54.06 % 18.26 % 20.45 %
Q1 2014 53.95 % 17.92 % 21.86 %
Q2 2014 53.91 % 17.74 % 20.28 %
Q3 2014 53.39 % 16.79 % 19.84 %
Q4 2014 54.03 % 18.15 % 21.50 %
Q1 2015 54.34 % 18.90 % 21.67 %
Q2 2015 53.23 % 18.31 % 20.04 %
Q3 2015 51.63 % 17.40 % 19.05 %
Q4 2015 49.19 % 17.17 % 19.11 %
Q1 2016 50.60 % 15.90 % 18.80 %
Q2 2016 52.04 % 15.52 % 16.88 %
Q3 2016 54.52 % 15.09 % 15.79 %
Q4 2016 56.62 % 10.25 % 5.68 %
Q1 2017 54.97 % 9.67 % 3.99 %
Q2 2017 54.34 % 11.85 % 4.64 %
Q3 2017 52.59 % 11.94 % 2.91 %
Q4 2017 50.83 % 14.96 % 9.94 %
Q1 2018 49.81 % 16.45 % 9.97 %
Q2 2018 50.07 % 14.49 % 8.30 %


Per Share Data (Riyal)

Compared With The
Period Shares Outstanding (M) EPS (Riyal) Adjusted EPS (Riyal) Book Value (BV)
Q1 2009 101.51 1.28 1.33 14.17
Q2 2009 101.51 1.32 1.36 17.62
Q3 2009 101.51 1.32 1.32 19.72
Q4 2009 101.51 1.53 1.56 21.46
Q1 2010 120.00 1.31 1.36 22.04
Q2 2010 120.00 1.36 1.41 19.98
Q3 2010 120.00 1.37 1.43 21.69
Q4 2010 120.00 1.47 1.50 24.48
Q1 2011 120.00 1.47 1.47 25.41
Q2 2011 120.00 1.62 1.62 27.29
Q3 2011 120.00 1.72 1.72 25.92
Q4 2011 120.00 1.75 1.75 26.50
Q1 2012 120.00 1.84 1.84 30.26
Q2 2012 120.00 2.09 2.09 25.75
Q3 2012 120.00 2.11 2.11 26.24
Q4 2012 120.00 1.94 1.94 25.28
Q1 2013 120.00 1.99 1.99 27.18
Q2 2013 120.00 2.19 2.19 26.14
Q3 2013 120.00 2.21 2.21 27.35
Q4 2013 120.00 2.23 2.23 32.18
Q1 2014 120.00 2.47 2.47 32.96
Q2 2014 120.00 2.33 2.33 33.21
Q3 2014 120.00 2.35 2.35 35.74
Q4 2014 120.00 2.64 2.64 28.75
Q1 2015 120.00 2.71 2.71 27.84
Q2 2015 120.00 3.87 2.61 28.72
Q3 2015 120.00 3.81 2.55 24.87
Q4 2015 120.00 2.98 2.70 22.17
Q1 2016 120.00 2.89 2.49 20.84
Q2 2016 120.00 1.24 2.10 20.49
Q3 2016 120.00 1.03 1.89 20.40
Q4 2016 120.00 2.31 0.60 22.59
Q1 2017 120.00 2.41 0.44 23.27
Q2 2017 120.00 2.47 0.50 21.52
Q3 2017 120.00 2.29 0.32 22.01
Q4 2017 120.00 1.64 1.15 22.78
Q1 2018 120.00 1.26 1.15 25.04
Q2 2018 120.00 1.06 0.95 25.74

Multiple Ratios (End of Period Price)

Compared With The
Period P/E Adjusted P/E Price/book
Q1 2009 14.92 14.39 1.35
Q2 2009 17.20 16.65 1.28
Q3 2009 18.29 18.26 1.22
Q4 2009 15.25 14.94 1.08
Q1 2010 16.69 16.04 0.99
Q2 2010 14.70 14.15 1.00
Q3 2010 14.64 14.10 0.93
Q4 2010 15.82 15.53 0.95
Q1 2011 17.65 17.65 1.02
Q2 2011 15.68 15.68 0.93
Q3 2011 14.41 14.41 0.96
Q4 2011 15.03 15.03 0.99
Q1 2012 17.92 17.92 1.09
Q2 2012 12.56 12.56 1.02
Q3 2012 13.70 13.70 1.10
Q4 2012 14.74 14.74 1.13
Q1 2013 13.60 13.60 1.00
Q2 2013 15.51 15.51 1.30
Q3 2013 15.70 15.70 1.27
Q4 2013 19.02 19.02 1.32
Q1 2014 19.07 19.07 1.43
Q2 2014 19.29 19.29 1.36
Q3 2014 21.41 21.41 1.41
Q4 2014 12.89 12.89 1.18
Q1 2015 14.78 14.78 1.44
Q2 2015 11.59 17.18 1.56
Q3 2015 9.46 14.14 1.45
Q4 2015 11.16 12.29 1.50
Q1 2016 11.15 12.96 1.55
Q2 2016 29.96 17.69 1.81
Q3 2016 30.18 16.49 1.53
Q4 2016 17.72 68.63 1.81
Q1 2017 15.03 81.82 1.56
Q2 2017 14.32 70.59 1.64
Q3 2017 14.43 More than 100 1.50
Q4 2017 18.25 26.14 1.32
Q1 2018 24.34 26.70 1.23
Q2 2018 30.03 33.56 1.24

Business Segments (Million)

Compared With The
Period Pharmaceutical Manufacturing healthy services and other Trading & Distribution Services Contract manufacturing arrangements Medical & Pharmaceutical production segment Investment activity Eliminations
Q1 2009 - - - - 257.88 - -
Q2 2009 - - - - 229.00 - -
Q3 2009 - - - - 171.15 - -
Q4 2009 - - - - 292.71 - -
Q1 2010 - - - - 274.33 - -
Q2 2010 - - - - 252.34 - -
Q3 2010 - - - - 191.41 - -
Q4 2010 - - - - 319.57 - -
Q1 2011 - - - - 252.08 - -
Q2 2011 - - - - 292.08 - -
Q3 2011 - - - - 209.24 - -
Q4 2011 - - - - 375.82 - -
Q1 2012 - - - - 303.14 - -
Q2 2012 - - - - 286.65 - -
Q3 2012 - - - - 227.40 - -
Q4 2012 - - - - 365.97 - -
Q1 2013 - - - - 361.37 - -
Q2 2013 - - - - 344.22 - -
Q3 2013 - - - - 222.91 - -
Q4 2013 - - - - 382.01 - -
Q1 2014 - - - - 405.21 - -
Q2 2014 - - - - 374.14 - -
Q3 2014 - - - - 266.02 - -
Q4 2014 - - - - 427.82 - -
Q1 2015 - - - - 432.29 14.84 -
Q2 2015 - - - - 436.99 195.93 -
Q3 2015 - - - - 308.38 9.55 -
Q4 2015 - - - - 529.24 - -
Q1 2016 - - - - 513.97 25.27 -
Q2 2016 - - - - 494.92 9.41 -
Q3 2016 - - - - 100.39 6.23 -
Q4 2016 - - - - 401.35 247.84 -
Q1 2017 - - - - 446.00 50.90 (51.45)
Q2 2017 - - - - 350.01 1.39 (43.30)
Q3 2017 - - - - 317.29 4.01 (36.78)
Q4 2017 - - - - 486.15 - (54.74)
Q1 2018 - - - - 450.19 7.00 (57.49)

Analysts Estimates (Million)

Item Q2 2018 (e) Q2 2018 (a) Change‬
Average 49.80 22.67 (54.5 %)

Estimates vs Actual (Million)

Item Q2 2018 (e) Q2 2018 (a) Change
OSOOL AND BAKHEET 49.80 22.67 (54.5) %


Financial Ratios
Current
Market Cap (M Riyal) 3,516.00
Enterprise Value (EV) (M) 4,597.48
Shares Outstanding ((M)) 120.00
EPS ( Riyal) (TTM) (0.27)
Book Value (BV) ( Riyal) 12.89
Par Value ( Riyal) 10.00
Adjusted P/E (Last12) Neg
P/E (TTM) NEG
Price/book 2.27
Return on Average Assets (%) (TTM) (0.76 )
Return on Average Equity (%) (TTM) (2.09 )
more

Share Price

Saudi Pharmaceutical Industries and Medical Appliances Corp.
29.20
(0.15) (0.51 %)

Saudi Pharmaceutical Industries and Medical Appliances Corp. (SPIMACO)

More

Comments {{getCommentCount()}}

Be the first to comment

{{Comments.indexOf(comment)+1}}
{{comment.FollowersCount}}
{{comment.CommenterComments}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}} حساب موثّق

{{comment.ElapsedTime}}
loader Train
loader Train
Sorry: the validity period has ended to comment on this news
Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.